Article info

Download PDFPDF
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?
  1. Correspondence to Professor Tim Warner, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; t.d.warner{at}qmul.ac.uk
View Full Text

Citation

Warner TD, Armstrong PCJ, Curzen NP, et al
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?

Publication history

  • Accepted August 24, 2010
  • First published October 18, 2010.
Online issue publication 
October 18, 2010

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.